New drug filgotinib shows promise for arthritis relief in korean study

NCT ID NCT06625242

Completed Disease control Sponsor: Eisai Korea Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 20 times

Summary

This study tested the drug filgotinib in 118 Korean adults with rheumatoid arthritis to see if it improves symptoms and controls disease activity. Participants took the drug for up to 24 weeks, and doctors measured joint pain, swelling, and inflammation. The goal was to see how many patients achieved at least a 20% improvement in symptoms by week 12.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Eisai site #01

Busan, South Korea
Eisai site #02

Gwangju, South Korea
Eisai site #03

Seoul, South Korea
Eisai site #04

Seoul, South Korea
Eisai site #05

Seoul, South Korea
Eisai site #06

Daejeon, South Korea
Eisai site #07

Seoul, South Korea
Eisai site #08

Seoul, South Korea
Eisai site #09

Daegu, South Korea
Eisai site #10

Seoul, South Korea
Eisai site #11

Anyang-si, South Korea
Eisai site #12

Daegu, South Korea
Eisai site #13

Incheon, South Korea
Eisai site #14

Seoul, South Korea
Eisai site #15

Guri-si, South Korea

Conditions

Explore the condition pages connected to this study.

RHEUMATOID ARTHRITIS